维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="Moesker"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Human bocavirus infection as a cause of severe acute respiratory tract infection in children显示文摘	F.M. Moesker J.J.A. van Kampen A.A. van der Eijk A.M.C. van Rossum M. de Hoog M. Schutten S.L. Smits R. Bodewes A.D.M.E. Osterhaus P.L.A. Fraaij	2015	Clinical Microbiology and Infection2015，，：	1
	2	The natural history of facial paralysis in herpes zoster 显示文摘	Devriese P P Moesker W H	1988	Clin Otolaryngol Allied Sci1988，13，4：	1
	3	Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview显示文摘	F. C. S. Ramaekers J. J. G. Puts O. Moesker A. Kant A. Huysmans D. Haag P. H. K. Jap C. J. Herman G. P. Vooijs	1983	The Histochemical Journal1983，，7：	1
	4	Human monoclonal an-tibodies induced by natural infection against West Nile Virus neu-tralize at a post-attachment step显示文摘	Vogt M R Moesker B Goudsmit J	2009	Virol2009，83，：	1
	5	Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients显示文摘	Suzanne Heemskerk Rosalinde Masereeuw Olof Moesker Martijn P. W. J. M. Bouw Johannes G. van der Hoeven Wilbert H. M. Peters Frans G. M. Russel Peter Pickkers	2009	Critical Care Medicine2009，，2：	1
	6	Safety and immu- nogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial显示文摘	Kreijtz JH Goeijenbier M Moesker FM	2014	Lancet Infect Dis2014，14，12：	1
	7	Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial 显示文摘	Kreijtz JH Goeijenbier M Moesker FM	2014	Lancet Infect Dis2014，14，：	1
	8	Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients显示文摘	Heemskerk S Masereeuw R Moesker O	2009	Crit Care Med2009，37，2：	1
	9	Systems biology applications to study mechanisms of human immunodeficiency virus latency and reactivation显示文摘Eradication of human immunodeficiency virus(HIV) in infected individuals is currently not possible because of the presence of the persistent cellular reservoir of latent infection. The identification of HIV latency biomarkers and a better understanding of the molecular mechanisms contributing to regulation of HIV expression might provide essential tools to eliminate these latently infected cells. This review aims at summarizing gene expression profiling and systems biology applications to studies of HIV latency and eradication. Studies comparing gene expression in latently infected and uninfected cells identify candidate latency biomarkers and novel mechanisms of latency control. Studies that profiled gene expression changes induced by existing latency reversing agents(LRAs) highlight uniting themes driving HIV reactivation and novel mechanisms that contribute to regulation of HIV expression by different LRAs. Among the reviewed gene expression studies, the common approaches included identification of differentially expressed genes and gene functional category assessment. Integration of transcriptomic data with other biological data types is presently scarce, and the field would benefit from increased adoption of these methods in future studies. In addition, designing prospective studies that use the same methods of data acquisition and statistical analyses will facilitate a more reliableidentification of latency biomarkers using different model systems and the comparison of the effects of different LRAs on host factors with a role in HIV reactivation. The results from such studies would have the potential to significantly impact the process by which candidate drugs are selected and combined for future evaluations and advancement to clinical trials.	Cory H White Bastiaan Moesker Angela Ciuffi Nadejda Beliakova-Bethell	2016	World Journal of Clinical Infectious Diseases2016，6，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费